Johnson & Johnson Vision to Acquire TearScience

August 4, 2017: By Jon Swedien

JJV logo x300Johnson & Johnson Vision announced Aug. 4 that it has signed a definitive agreement to acquire TearScience, a Morrisville, North Carolina, company that develops and markets products for meibomian gland dysfunction (MGD), an underlying cause of dry eye disease.

Financial terms were not disclosed.

The deal is expected to close by the end of the year, J&J Vision said. Following the closing, sales will be reported in J&J’s Medical Devices segment, under Vision Care, the company said. J&J Vision’s ophthalmic surgery division is located in Santa Ana, California.

TearScience received FDA clearance in July 2011 for its LipiFlow system, an office-based approach to image meibomian glands and treat MGD. The company sells its products in the US and major markets globally, J&J Vision said.

The TearScience acquisition strengthens J&J Vision’s portfolio, allowing it to provide a critical solution to its optometric and ophthalmic customers who serve dry eye patients, company officials said.


Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

EyeGate’s EGP-437 for Post-Cataract Pain, Inflammation Produces Mixed Results in Phase IIb Trial

Second Sight Reports Record Number of Argus II Implants in Q4-2017, First Orion Implant in Human

Allergan Appoints Matthew Walsh as CFO

Ocunova Secures $500 Thousand From Two Firms to Pursue Dry Eye Treatment for Diabetic Patients

ReVision Optics Closes Doors; Raindrop Corneal Inlay No Longer Available

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023